---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000957"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T16:47:49.675536+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted

## Summary
- Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.
- Received inducement grant for 100K shares ($1.46) vesting monthly over 3 years; additional 50K shares vesting over 1 year.
- Board size increased from 7 to 8 members.
- Skerjanec led Roche's Ocrevus commercial launch, generating over $1B in first 10 months.
- Company approaching late-stage readouts for vidofludimus calcium in MS; recently hired ex-Novartis/Biogen COO.

## SEC filing metadata
- accession: 0001193805-24-000957
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/0001193805-24-000957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/e663800_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000957
- JSON: https://secwatch.observer/filing/0001193805-24-000957.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000957.txt

## Key facts
- Executive change
  Simona Skerjanec was appointed as Director at IMMUNIC, INC..
  - Action: appointed
  - Role: Director
  source text: On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000957/0001193805-24-000957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.